Please provide your email address to receive an email when new articles are posted on . Risk-reducing salpingo-oophorectomy may offer dissimilar protection against breast and gynecologic cancers to ...

A retrospective study was performed to assess the histopathologic findings in high-risk women undergoing bilateral prophylactic (salpingo)-oophorectomy. The medical files of BRCA1 or BRCA2 mutation ...

Undergoing prophylactic salpingo-oophorectomy (PSO) after previous surgery for BRCA1/BRCA2 breast cancer was associated with a significantly reduced risk of death, according to an Italian ...

A study of over 200,500 women who had a hysterectomy for non-cancerous reasons found an increased risk of death in women under 50 years of age when the ovaries and fallopian tubes were also removed ...

The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis (PC) in BRCA1/2 ...

Prophylactic salpingo-oophorectomy -- removal of the ovaries and fallopian tubes -- reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Risk-reducing salpingo-oophorectomy was ...

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 ...

Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Background: Risk-reducing salpingo-oophorectomy ...

A history of bilateral salpingo-oophorectomy does not reduce the odds of death from cardiovascular disease among postmenopausal women with type 2 diabetes, although there may be an association between ...

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA) Unpublished data from three centers ...